FDA’s Center for Tobacco Products outlines steps to strengthen tobacco program

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA’s Center for Tobacco Products published the actions it plans to take in response to an external evaluation commissioned last year from an independent panel of evaluators working through the Reagan-Udall Foundation.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe


Energy and Commerce Committee Health Subcommittee Ranking Member Rep. Anna G. Eshoo (D-CA), Ranking Member Rep. Frank Pallone, Jr. (D-NJ), and Oversight and Investigations Subcommittee Ranking Member Rep. Kathy Castor (D-FL) wrote to FDA Commissioner Robert M. Califf to urge the agency to move forward with guidance to improve the diversity of populations represented in clinical trials.